awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q33949406-51DAFF5B-26B5-455D-BF59-8B531F93D724
Q33949406-51DAFF5B-26B5-455D-BF59-8B531F93D724
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33949406-51DAFF5B-26B5-455D-BF59-8B531F93D724
Risks and benefits with bevacizumab: evidence and clinical implications.
P2860
Q33949406-51DAFF5B-26B5-455D-BF59-8B531F93D724
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33949406-51DAFF5B-26B5-455D-BF59-8B531F93D724
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
88617659ca7f9c2f06e89fbbd9b97c5da306cde4
P2860
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.